Technical Analysis for BLTE - Belite Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 81.66 | -1.05% | -0.87 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | -1.05% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -1.05% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.05% | |
| NR7 | Range Contraction | -1.05% | |
| Narrow Range Bar | Range Contraction | -1.05% | |
| Inside Day | Range Contraction | -1.05% | |
| Wide Bands | Range Expansion | -1.05% | |
| Overbought Stochastic | Strength | -1.05% | |
| Wide Bands | Range Expansion | -0.83% | |
| Overbought Stochastic | Strength | -0.83% |
| Alert | Time |
|---|---|
| Down 1% | 16 minutes ago |
| Fell Below 10 DMA | 16 minutes ago |
| 60 Minute Opening Range Breakdown | 24 minutes ago |
| 10 DMA Support | about 19 hours ago |
| Fell Below 10 DMA | about 20 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/12/2024
Belite Bio, Inc. Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Diabetes Drug Development Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Oral Therapy Stargardt Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 86.53 |
| 52 Week Low | 31.005 |
| Average Volume | 69,547 |
| 200-Day Moving Average | 49.39 |
| 50-Day Moving Average | 61.25 |
| 20-Day Moving Average | 75.43 |
| 10-Day Moving Average | 81.96 |
| Average True Range | 4.03 |
| RSI (14) | 72.30 |
| ADX | 33.7 |
| +DI | 28.43 |
| -DI | 13.98 |
| Chandelier Exit (Long, 3 ATRs) | 74.44 |
| Chandelier Exit (Short, 3 ATRs) | 67.59 |
| Upper Bollinger Bands | 90.31 |
| Lower Bollinger Band | 60.55 |
| Percent B (%b) | 0.74 |
| BandWidth | 39.46 |
| MACD Line | 6.60 |
| MACD Signal Line | 6.62 |
| MACD Histogram | -0.0199 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 85.52 | ||||
| Resistance 3 (R3) | 85.51 | 84.50 | 85.02 | ||
| Resistance 2 (R2) | 84.50 | 83.74 | 84.51 | 84.85 | |
| Resistance 1 (R1) | 83.52 | 83.27 | 83.02 | 83.53 | 84.69 |
| Pivot Point | 82.51 | 82.51 | 82.26 | 82.52 | 82.51 |
| Support 1 (S1) | 81.53 | 81.75 | 81.03 | 81.54 | 80.37 |
| Support 2 (S2) | 80.52 | 81.28 | 80.53 | 80.21 | |
| Support 3 (S3) | 79.54 | 80.52 | 80.04 | ||
| Support 4 (S4) | 79.55 |
